Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.80 |
| ▸ | MAPT | P10636 | 3/20 | 0.80 |
| ▸ | CNR1 | P21554 | 3/20 | 0.80 |
| ▸ | THRB | P10828 | 1/20 | 0.80 |
| ▸ | FAAH | O00519 | 3/20 | 0.65 |
| ▸ | PPARG | P37231 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.62 |
| ▸ | FABP4 | P15090 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | CASP1 | P29466 | 1/20 | 0.62 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3656524 | 1.00 | MGLL (0.82) | MGLLALDH1A1MAPTCNR1THRB | |
| SCHEMBL3656522 | 1.00 | MGLL (0.82) | MGLLALDH1A1MAPTCNR1THRB | |
| SCHEMBL25290964 | 0.98 | MGLL (0.80) | MGLLALDH1A1MAPTCNR1THRB | |
| SCHEMBL25286022 | 0.98 | MGLL (0.80) | MGLLALDH1A1MAPTCNR1THRB | |
| SCHEMBL25293178 | 0.98 | MGLL (0.80) | MGLLALDH1A1MAPTCNR1THRB | |
| SCHEMBL25246353 | 0.98 | MGLL (0.80) | MGLLALDH1A1MAPTCNR1THRB | |
| SCHEMBL25290861 | 0.98 | MGLL (0.80) | MGLLALDH1A1MAPTCNR1THRB | |
| SCHEMBL25293628 | 0.98 | MGLL (0.80) | MGLLALDH1A1MAPTCNR1THRB | |
| SCHEMBL25292755 | 0.98 | MGLL (0.80) | MGLLALDH1A1MAPTCNR1THRB | |
| SCHEMBL23779987 | 0.98 | MGLL (0.80) | MGLLALDH1A1MAPTCNR1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309273-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-10-16 | — | — | US | claimed |
| US-20110178151-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW (IL) | 2011-07-21 | — | — | US | claimed |
| EP-2262763-A2 | COMPOUNDS AND METHODS OF TREATING OBESITY | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2010-12-22 | — | — | EP | claimed |
| WO-2009109973-A2 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2009-09-11 | — | — | WO | claimed |
| US-9428448-B2 | Compounds and methods of treating obesity | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2016-08-30 | — | — | US | disclosed |
| US-20140309273-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-10-16 | — | — | US | disclosed |
| US-20110178151-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW (IL) | 2011-07-21 | — | — | US | disclosed |
| EP-2262763-A2 | COMPOUNDS AND METHODS OF TREATING OBESITY | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009109973-A2 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309273-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | FABP4, LIPC, GPR119 | MGLL 61/4885ALDH1A1 939/4885MAPT 1065/4885 |
| US-20110178151-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | GPR119, FABP4, LIPC | MGLL 65/4885ALDH1A1 933/4885MAPT 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.